Perfil
Andreas Klostermann was the founder and former Chief Executive Officer of conoGenetix biosciences GmbH, a company he founded in 2002.
He held this position until 2017.
Dr. Klostermann is also the founder of selectION, Inc. Currently, he serves as the Director of The Education Foundation of the Forest Lake Area.
Cargos activos de Andreas Klostermann
| Empresas | Cargo | Inicio |
|---|---|---|
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Fundador | - |
| The Education Foundation of the Forest Lake Area | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Andreas Klostermann.
| Empresas | Cargo | Fin |
|---|---|---|
conoGenetix biosciences GmbH
 conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Director Ejecutivo | 01/10/2017 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Health Technology |
| The Education Foundation of the Forest Lake Area | |
conoGenetix biosciences GmbH
conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Andreas Klostermann